Overview

AC-262536 is an investigational selective androgen receptor modulator (SARM) developed as a potential therapeutic agent for muscle wasting conditions. Unlike traditional anabolic steroids, SARMs are designed to selectively target androgen receptors in muscle and bone tissue while minimizing effects on other organs such as the prostate and liver.

Important Note: AC-262536 is not approved for human use and remains an experimental research compound. It is prohibited by the World Anti-Doping Agency (WADA) for competitive athletes.

The compound was initially developed by Acadia Pharmaceuticals as part of their SARM research program, though development appears to have been discontinued. Limited preclinical research suggests tissue-selective anabolic activity, but comprehensive safety and efficacy data in humans is lacking.

Mechanism of Action

AC-262536 functions as a selective androgen receptor modulator, binding to androgen receptors with tissue selectivity. The proposed mechanism includes:

Selective Receptor Binding:

• Binds to androgen receptors in skeletal muscle tissue
• Demonstrates reduced binding affinity for receptors in reproductive tissues
• May exhibit partial agonist activity at the androgen receptor

Anabolic Signaling:

• Activates protein synthesis pathways in muscle tissue
• May influence muscle fiber growth and repair mechanisms
• Potentially modulates satellite cell activation

Tissue Selectivity:

• Designed to minimize androgenic effects on prostate, liver, and reproductive organs
• May reduce risk of traditional steroid-associated side effects
• Selectivity mechanism not fully characterized

Research Summary

Research on AC-262536 is extremely limited, with no published human clinical trials and minimal preclinical data available in peer-reviewed literature. The compound appears to have been discontinued from formal development.

Key Studies

Preclinical Research:

• Limited animal studies suggest anabolic activity in muscle tissue
• Tissue selectivity demonstrated in rodent models
• Safety profile not comprehensively characterized

Current Status:

• No active clinical trials registered
• Development discontinued by original manufacturer
• Available primarily through research chemical suppliers

Dosage Guidelines

No established dosage protocols exist for AC-262536 due to lack of clinical research.

Anecdotal reports from research use suggest:

Important: These parameters are based solely on uncontrolled user reports and have no scientific validation. Use carries significant unknown risks.

Safety Profile

The safety profile of AC-262536 in humans is unknown due to absence of clinical trials.

Potential Concerns:

• Hepatotoxicity: Unknown liver safety profile
• Cardiovascular effects: Impact on lipid levels unknown
• Hormonal suppression: Effects on natural testosterone production unclear
• Long-term effects: No data on chronic use consequences

Reported Side Effects (Unverified):

• Mild suppression of natural hormone production
• Potential fatigue during use
• Unknown impact on cholesterol levels

Monitoring Recommendations: If used for research purposes, comprehensive monitoring should include:

• Complete blood count
• Comprehensive metabolic panel
• Lipid profile
• Hormone panel (testosterone, LH, FSH)
• Liver function tests

Stacking

Given the experimental nature and unknown safety profile of AC-262536, stacking with other compounds significantly increases risk and is not recommended.

Theoretical Considerations:

• Combining with other SARMs may compound unknown risks
• Interaction with peptides or growth factors not studied
• Post-cycle therapy requirements unknown

Risk Mitigation:

• If used experimentally, use as single agent only
• Avoid combination with hepatotoxic substances
• Consider natural testosterone support compounds

Note: Any use of AC-262536 should be considered experimental research with significant unknown risks. The compound is not approved for human consumption and carries potential for serious adverse effects.